Do GLP-1s Cause Acid Reflux and GERD? What the 2025 Evidence Shows

Acid reflux is one of the quieter side effects of GLP-1 medications, and for years the evidence behind it was mostly anecdotal. That changed in 2025, when a large cohort study put a real number on the risk and a separate line of research showed why the same mechanism that drives weight loss can also push stomach acid back up the esophagus. This guide walks through what the data actually shows, how strong it is, and what you can do about it.

The Short Version of What We Know

GLP-1 medications slow how fast your stomach empties. That is not a bug. It is part of how drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) make you feel full and eat less. But a stomach that empties slowly stays fuller and more pressurized for longer, and that creates the conditions for acid to escape upward into the esophagus.

The best evidence to date suggests GLP-1 users do face a modestly higher risk of gastroesophageal reflux disease (GERD) than people on a comparable diabetes drug. The increase is real but not enormous. And there is a genuine twist: over the longer term, the weight loss these drugs produce can actually relieve reflux for some people, because excess abdominal fat is itself a major driver of GERD. So the honest answer is that GLP-1s can both cause and ease reflux, depending on the person and the timeframe.

This article grades that evidence carefully. Reflux is rarely dangerous, but it is common enough on these drugs that it is worth understanding before you start.

How GLP-1 Medications Can Trigger Reflux

To understand the reflux risk, you have to understand what these drugs do to your stomach.

The Mechanism: Slowed Gastric Emptying

GLP-1 receptor agonists mimic a gut hormone that, among other things, tells your stomach to slow down. When you take one, the muscular activity that normally pushes food out of the stomach and into the small intestine is dampened. The fundus (the upper part of the stomach) relaxes, the antrum (the lower part) contracts less, and the pylorus (the valve at the stomach exit) tightens. Food and acid sit in the stomach longer.

This is exactly why the drugs work. A slower-emptying stomach keeps you fuller and blunts the blood-sugar spike after meals. But there is a price. A fuller stomach holds more volume and more pressure. When pressure inside the stomach rises above the strength of the lower esophageal sphincter (the ring of muscle that is supposed to keep acid down), reflux happens. You feel it as heartburn, a sour taste, or regurgitation.

There may be a second mechanism beyond pressure. GLP-1 signaling acts partly through the vagus nerve, which also helps coordinate the lower esophageal sphincter. Some researchers think the drugs may subtly alter sphincter tone, not just stomach volume. This part is less settled, and the dominant explanation remains the simple one: a fuller stomach for longer means more chances for acid to back up. The FDA's official labeling for semaglutide lists gastrointestinal effects, including reflux and the well-documented delay in gastric emptying, among the recognized class effects; see the FDA semaglutide safety information page for the regulator's summary.

Why Timing Matters

The slowing effect is strongest in the first weeks of treatment and during dose increases. That is also when nausea, fullness, and reflux complaints peak. As your body adapts to a stable dose over roughly four to eight weeks, gastric emptying often partly normalizes and many symptoms ease. Short-acting GLP-1s tend to slow emptying more sharply per dose, while the long-acting weekly drugs most people take now (semaglutide, dulaglutide, tirzepatide) produce a steadier, more sustained effect.

The Weight-Loss Counterweight

Here is what makes this complicated. Obesity is one of the strongest risk factors for GERD. Extra abdominal fat physically pushes up on the stomach and raises the pressure gradient that drives reflux. As GLP-1 users lose weight, that pressure drops. For someone who had bad reflux driven mostly by their weight, losing 15 to 20 percent of body weight can improve heartburn well beyond where it started. So the drug's two main effects pull in opposite directions: slowed emptying nudges reflux up, weight loss nudges it down.

What the 2025 Evidence Actually Shows

For a long time, reflux on GLP-1s was supported mainly by trial side-effect tallies and patient reports. In 2025 the evidence got sharper.

The Largest Study: A Population Cohort

The most important study came out in the Annals of Internal Medicine in September 2025. Researchers used a large UK primary-care database to compare adults with type 2 diabetes who started a GLP-1 receptor agonist against those who started an SGLT-2 inhibitor (a different diabetes drug used as a fair comparison group). They followed about 24,700 GLP-1 users and about 89,100 SGLT-2 users for a median of three years, and they excluded people who already had reflux.

The findings:

Outcome	GLP-1 vs SGLT-2 comparison	Plain-language meaning
New GERD diagnosis	Risk ratio 1.27 (95% CI 1.14–1.42)	About 27% higher relative risk
GERD complications (e.g., esophagitis, stricture)	Risk ratio 1.55 (95% CI 1.12–2.29)	About 55% higher relative risk
Absolute extra GERD cases	~0.7 more per 100 patients	Small in absolute terms
Absolute extra complications	~0.8 more per 1,000 patients	Rare in absolute terms

The key takeaway is the gap between relative and absolute risk. A 27 percent higher relative risk sounds alarming, but it translates to fewer than one extra GERD case per 100 people over three years. Complications were rarer still. The signal is real and statistically solid, but the day-to-day burden for most users is modest.

What This Study Can and Cannot Tell You

This was an observational cohort, not a randomized trial. That matters. It was carefully designed with an active comparator and exclusions for prior reflux, which strengthens it. But observational data can never fully rule out that something other than the drug explains the difference. The study was also in people with type 2 diabetes, not in people taking GLP-1s purely for weight loss, so the numbers may not transfer exactly to the Wegovy or Zepbound population.

Evidence grade for "GLP-1s raise GERD risk in diabetes": moderate. One large, well-designed cohort points clearly in one direction, but it is a single study and observational.

It is also worth being precise about what "GERD diagnosis" meant in this study. It captured new diagnoses recorded in primary-care records, which can lag behind actual symptoms and depends on patients reporting heartburn and doctors coding it. That can cut both ways: some real reflux never gets diagnosed, and some people on a new drug see their doctor more often and get diagnosed sooner simply because they are being watched more closely. Researchers try to account for this, but no observational design fully removes it. The complication outcomes (esophagitis, stricture, and similar) are harder to miss and harder to over-diagnose, which is part of why the higher relative risk for complications is a meaningful finding even though the absolute number stayed low.

What Clinical Trials Showed

The randomized obesity trials add supporting context. In the semaglutide weight-loss program, gastrointestinal events were the most common side effects, dominated by nausea, vomiting, and diarrhea during dose escalation. Reflux appeared as a less frequent but recognized event. A detailed look at GI tolerability in the semaglutide 2.4 mg obesity trial program found most GI events were mild to moderate and clustered around dose increases, and that they did not, on average, drive the weight loss. Reflux-type symptoms were reported by a minority of participants, consistent with a real but not dominant effect.

The Endoscopy and Stomach-Content Signal

A separate line of 2025 research looked at what is physically in the stomach. A study published in Cureus in 2025 examined patients having upper endoscopy. Among those on semaglutide or tirzepatide for more than six months, 91.7 percent (11 of 12) had significant retained stomach contents, versus zero of 132 patients on the drugs for under six months. The sample on long-term therapy was tiny, so treat the exact percentage with caution, but the direction confirms the mechanism: these drugs really do leave food sitting in the stomach longer, sometimes for many hours after fasting.

That retained content is the link between the drug and reflux, and it is also why there has been concern about a related but separate risk during sedation: aspiration.

The Aspiration Question (A Related But Separate Risk)

Because GLP-1s leave food in the stomach, doctors worried that patients under sedation for procedures like endoscopy or surgery might inhale (aspirate) that content into the lungs. This led to new perioperative guidance and a lot of headlines. It is worth separating from everyday heartburn.

A 2025 systematic review and meta-analysis pooled 12 studies and more than 210,000 patients having elective upper endoscopy. Aspiration occurred in 0.16 percent of GLP-1 users versus 0.12 percent of non-users, with an odds ratio of 1.23 that was not statistically significant (95% CI 0.58–2.60). In plain terms: aspiration during endoscopy is rare in everyone, and this pooled analysis did not find a clear, proven increase from GLP-1s, though individual case reports of aspiration despite fasting exist and keep clinicians cautious.

In response to the concern, gastroenterology and anesthesiology societies issued multisociety perioperative guidance in 2024 that moved toward a risk-based approach rather than blanket drug-holding. Practical upshot for you: tell every doctor and anesthesiologist that you take a GLP-1, ask whether to hold a dose before a procedure, and follow any extended-fasting or clear-liquid-diet instructions they give.

Evidence grade for "GLP-1s meaningfully raise aspiration risk during sedation": low to uncertain. The mechanism is real, but pooled outcome data so far do not show a clear increase.

GERD on GLP-1s Compared With Other Causes

It helps to put the GLP-1 reflux risk in context with other common drivers of heartburn.

Reflux driver	Relative strength	How it relates to GLP-1s
Obesity / excess abdominal fat	Strong, well established	GLP-1 weight loss reduces this over time
Delayed gastric emptying	Moderate, mechanistic	This is the GLP-1 side effect that adds risk
Hiatal hernia	Strong, anatomical	Unchanged by GLP-1s; worth knowing if you have one
Large, fatty, late-night meals	Moderate, behavioral	Easier to overdo early on; small meals help a lot
Smoking and alcohol	Moderate	Independent risk; matters more on a GLP-1
Pre-existing GERD	Strong	GLP-1s can worsen it during titration

The practical message is that GLP-1 reflux usually does not happen in a vacuum. It tends to flare in people who already have other risk factors stacked on top, especially in the first weeks. Researchers found the highest risk of serious GERD complications among smokers, people with obesity, and those with existing stomach problems.

The Long-Term Picture Is Different From the Short-Term One

This is the part that gets lost in headlines. The cohort study measured GERD over three years and still found a net increase, so the slowed-emptying effect does not simply vanish. But within an individual, the balance can shift over time. In the first weeks, slowed emptying dominates and reflux is most likely to appear or worsen. Months later, after meaningful weight loss, the reduction in abdominal pressure can offset or even outweigh the emptying effect for some people.

That is why two users can have opposite experiences and both be telling the truth. A lean person with diabetes taking a GLP-1 for blood sugar gets the slowed-emptying downside with little weight-loss upside on reflux, so they are more likely to notice new heartburn. A heavier person taking it for weight loss may get a rough first month and then find their long-standing reflux is the best it has been in years. The averages in a study can hide these two stories canceling each other out.

There is also a smaller body of observational work suggesting GLP-1 use is associated with reduced proton pump inhibitor use over time in some populations, which would be consistent with reflux improving as weight comes off. That evidence is weaker and less consistent than the cohort data showing increased GERD, so it should be read as suggestive rather than proven.

Comparing Across Drugs

Does the drug you choose change your reflux risk? The honest answer is that the head-to-head reflux data are thin. The big cohort study grouped GLP-1s together rather than ranking individual drugs for reflux. Mechanistically, tirzepatide (which hits both GLP-1 and GIP receptors) and high-dose semaglutide are potent and produce strong, sustained slowing of gastric emptying, so it is reasonable to expect their reflux profile to track their overall GI intensity. But there is no good evidence that switching from one modern weekly GLP-1 to another reliably fixes reflux. The bigger levers are dose, titration speed, and meal habits, not brand choice.

Managing Reflux While Staying on a GLP-1

The good news is that most reflux on these drugs is manageable without stopping treatment. The first moves are behavioral.

Diet and Eating Habits

• Eat smaller portions. A stomach that empties slowly cannot handle big meals, and overfilling it is the fastest route to reflux.
• Stop eating two to three hours before lying down. Gravity is your friend.
• Go easy on the classic triggers: fried and fatty foods, large amounts of coffee, chocolate, peppermint, citrus, tomato, carbonated drinks, and alcohol.
• Slow down. Eating quickly on a GLP-1 reliably brings on fullness and reflux.

Position and Lifestyle

• Raise the head of your bed by six to eight inches, or use a wedge pillow, if you get nighttime reflux.
• Avoid tight waistbands, which raise abdominal pressure.
• If you smoke, this is one more reason to quit; smoking weakens the sphincter that holds acid down.

Medication Options

• Antacids (like calcium carbonate) help with occasional, mild heartburn.
• H2 blockers (famotidine) reduce acid for several hours and are useful for predictable evening symptoms.
• Proton pump inhibitors (omeprazole, esomeprazole) are the strongest acid reducers and are appropriate for frequent or persistent reflux, but they should be used under a clinician's guidance, especially long term.

Always check with your prescriber or pharmacist before adding an acid reducer, since timing relative to other medications can matter and persistent symptoms deserve evaluation.

When to Slow the Dose

If reflux is bad, the titration schedule is often the lever. Spending longer at a lower dose, or stepping the dose down temporarily, can ease symptoms while your stomach adapts. This is a conversation to have with your prescriber rather than a change to make on your own.

When Reflux Is a Red Flag

Most heartburn on a GLP-1 is a nuisance, not an emergency. But some symptoms warrant prompt medical attention rather than self-treatment:

• Trouble or pain when swallowing, or food feeling stuck
• Vomiting that will not stop, or vomiting blood or material that looks like coffee grounds
• Black, tarry stools
• Unintentional weight loss beyond what the drug would explain, or new loss of appetite with pain
• Chest pain (always rule out a cardiac cause, especially if you have heart risk factors)
• Reflux that does not respond to standard treatment after a few weeks

These can signal esophagitis, stricture, bleeding, or something unrelated to reflux entirely, and they need a clinician's evaluation.

Who Should Be Extra Cautious

GLP-1s are not off the table for people prone to reflux, but a few groups should go in with their eyes open and a plan in place.

People with established GERD or a hiatal hernia are the clearest example. The Annals cohort suggests existing stomach problems raise the odds of complications, so these patients benefit from slower titration, proactive acid control, and closer follow-up. People with known gastroparesis (a stomach that already empties too slowly) are generally steered away from GLP-1s, because the drug compounds the problem. Smokers and people carrying a lot of abdominal weight start with more baseline risk, though the weight loss may help them most in the long run. And anyone scheduled for surgery or endoscopy needs to flag their GLP-1 use ahead of time.

For most people without these factors, mild reflux during dose escalation is the likely worst case, and it usually fades.

How This Fits the Bigger Side-Effect Picture

Reflux is one item on a longer list of GI effects tied to slowed gastric emptying, and they tend to travel together. If you want the full landscape, see our complete guide to GLP-1 side effects and the deeper dive on GLP-1 medications, side effects, and risks. Nausea is the most common complaint and overlaps heavily with reflux; our guide to managing Ozempic nausea with evidence-based tips covers tactics that also help reflux. For the more serious end of the slowed-emptying spectrum, read about GLP-1s and gastroparesis, which shares the same underlying mechanism as reflux but is far less common.

Frequently Asked Questions

Do GLP-1 medications cause acid reflux?

They can. The best 2025 evidence, a large cohort study in people with type 2 diabetes, found about a 27 percent higher relative risk of new GERD on GLP-1s versus a comparable diabetes drug. The absolute increase was small (fewer than one extra case per 100 people over three years). The mechanism is slowed stomach emptying, which keeps the stomach fuller and more pressurized.

Does GLP-1 reflux go away on its own?

Often, yes. Reflux tends to be worst in the first weeks and during dose increases, then eases over about four to eight weeks as your body adapts to a stable dose. For people whose reflux was driven by excess weight, ongoing weight loss can improve heartburn beyond where it started. Persistent or worsening reflux should be checked by a clinician.

Can I take an acid reducer like omeprazole with my GLP-1?

Generally yes, but talk to your prescriber or pharmacist first. Antacids and H2 blockers like famotidine are fine for occasional heartburn. Proton pump inhibitors like omeprazole work well for frequent reflux but are best used under medical guidance, especially for the long term, and dosing timing relative to other medicines can matter.

Are GLP-1s dangerous before surgery or an endoscopy because of reflux?

The concern is aspiration of retained stomach contents under sedation, not heartburn itself. A 2025 meta-analysis did not find a clearly significant increase in aspiration during endoscopy, but the risk is taken seriously. Tell your surgeon and anesthesiologist you take a GLP-1, and follow their instructions on holding a dose and extended fasting.

Should I stop my GLP-1 if I get heartburn?

Usually not. Most reflux is manageable with smaller meals, avoiding late eating, trigger-food changes, and short-term acid reducers. If symptoms are severe, slowing the titration or temporarily lowering the dose often helps. Make dose changes with your prescriber rather than stopping abruptly on your own.

This article is for general information only and is not medical advice. Talk to your doctor or pharmacist before starting, stopping, or changing any medication, or if you have persistent reflux symptoms.